University Hospital, Department of Urology, Patras, Greece

The antitumour activity of NSAIDs in preclinical trials has lead to their evaluation in the management of various malignancies in humans. Evidence regarding their use in the treatment of genitourinary tumours is reviewed here, focusing primarily on clinical data. The majority of available evidence comes from meeting abstracts and only a few published manuscripts were detected. The efficacy of selective COX-2 inhibitors, a subcategory of anti-inflammatory drugs, is promising in prostate cancer, in either biochemical recurrence after initial treatment or advanced disease. This does not seem to be the case for renal tumours in which efficacy in the advanced disease setting is not satisfactory. Despite the well-documented rationale for the application of NSAIDs in bladder cancer management, clinical evidence is not available. More studies are needed to assess the efficacy of anti-inflammatory agents in bladder cancer treatment and further clarify their therapeutic benefit in patients with prostate cancer, in which initial results are encouraging.

Written by
Giannitsas K, Konstantinopoulos A, Perimenis P.

Reference
Expert Opin Investig Drugs. 2007 Nov;16(11):1841-9
doi:10.1517/13543784.16.11.1841

PubMed Abstract
PMID:17970642

UroToday.com Bladder Cancer Section

UroToday.com Prostate Cancer Section

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!